Actualités Camurus Ab - 0RD1 | Actions London Stock Exchange

Camurus announces new Phase 3 data reinforcing long-term safety and efficacy of octreotide SC depot (CAM2029) in patients with acromegaly

Camurus announces new Phase 3 data reinforcing long-term safety and efficacy of octreotide SC depot (CAM2029) in patients with acromegaly PR...

Camurus announces new Phase 3 data reinforcing long-term safety and efficacy of octreotide SC depot (CAM2029) in patients with acromegaly

Camurus announces new Phase 3 data reinforcing long-term safety and efficacy of octreotide SC depot (CAM2029) in patients with acromegaly PR...

Camurus announces FDA approval of Brixadi™ for the treatment of moderate to severe opioid use disorder

Camurus announces FDA approval of Brixadi™ for the treatment of moderate to severe opioid use disorder PR Newswire LUND, Sweden, May 24, 2023...

Camurus announces FDA approval of Brixadi™ for the treatment of moderate to severe opioid use disorder

Camurus announces FDA approval of Brixadi™ for the treatment of moderate to severe opioid use disorder PR Newswire LUND, Sweden, May 24, 2023...

Braeburn receives new Complete Response Letter for Brixadi in the US

Braeburn receives new Complete Response Letter for Brixadi in the US PR Newswire LUND, Sweden, Dec. 15, 2021 LUND, Sweden, Dec. 15, 2021...

FDA grants Orphan Drug Designation in the US for CAM2029 for the treatment of polycystic liver disease

FDA grants Orphan Drug Designation in the US for CAM2029 for the treatment of polycystic liver disease PR Newswire LUND, Sweden, Sept. 16, 2021...

FDA grants Orphan Drug Designation in the US for CAM2029 for the treatment of polycystic liver disease

FDA grants Orphan Drug Designation in the US for CAM2029 for the treatment of polycystic liver disease PR Newswire LUND, Sweden, Sept. 16, 2021...

Camurus announces PDUFA date for Brixadi for the treatment of opioid use disorder in the US

Camurus announces PDUFA date for Brixadi for the treatment of opioid use disorder in the US PR Newswire LUND, Sweden, June 26, 2021 New PDUFA...

Camurus announces PDUFA date for Brixadi for the treatment of opioid use disorder in the US

Camurus announces PDUFA date for Brixadi for the treatment of opioid use disorder in the US New PDUFA action date for Brixadi set for 15 December...

Camurus announces Braeburn resubmits New Drug Application for Brixadi™ in the US

Camurus announces Braeburn resubmits New Drug Application for Brixadi™ in the US PR Newswire LUND, Sweden, June 15, 2021 LUND, Sweden, June 15...

Camurus announces Braeburn resubmits New Drug Application for Brixadi™ in the US

Camurus announces Braeburn resubmits New Drug Application for Brixadi™ in the US PR Newswire LUND, Sweden, June 15, 2021 LUND, Sweden, June 15...

Camurus announces publication showing superior patient treatment satisfaction with Buvidal® weekly and monthly depot injecti...

Camurus announces publication showing superior patient treatment satisfaction with Buvidal® weekly and monthly depot injections in opioid...

Camurus announces publication showing superior patient treatment satisfaction with Buvidal® weekly and monthly depot injecti...

Camurus announces publication showing superior patient treatment satisfaction with Buvidal® weekly and monthly depot injections in opioid...

The Australian TGA approves key label updates to Buvidal® for treatment of opioid dependence

The Australian TGA approves key label updates to Buvidal® for treatment of opioid dependence PR Newswire LUND, Sweden, May 3, 2021 LUND, Sweden...

The Australian TGA approves key label updates to Buvidal® for treatment of opioid dependence

The Australian TGA approves key label updates to Buvidal® for treatment of opioid dependence PR Newswire LUND, Sweden, May 3, 2021 LUND, Sweden...

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Camurus Ab (0RD1)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

0RD1 Actualités

Camurus announces new Phase 3 data reinforcing long-term safety and efficacy of octreotide SC depot (CAM2029) in patients with acromegaly

Camurus announces new Phase 3 data reinforcing long-term safety and efficacy of octreotide SC depot (CAM2029) in patients with acromegaly

Camurus announces FDA approval of Brixadi™ for the treatment of moderate to severe opioid use disorder

Camurus announces FDA approval of Brixadi™ for the treatment of moderate to severe opioid use disorder

Braeburn receives new Complete Response Letter for Brixadi in the US

FDA grants Orphan Drug Designation in the US for CAM2029 for the treatment of polycystic liver disease

FDA grants Orphan Drug Designation in the US for CAM2029 for the treatment of polycystic liver disease

Camurus announces PDUFA date for Brixadi for the treatment of opioid use disorder in the US

Camurus announces PDUFA date for Brixadi for the treatment of opioid use disorder in the US

Camurus announces Braeburn resubmits New Drug Application for Brixadi™ in the US

Camurus announces Braeburn resubmits New Drug Application for Brixadi™ in the US

Camurus announces publication showing superior patient treatment satisfaction with Buvidal® weekly and monthly depot injecti...

Camurus announces publication showing superior patient treatment satisfaction with Buvidal® weekly and monthly depot injecti...

The Australian TGA approves key label updates to Buvidal® for treatment of opioid dependence

The Australian TGA approves key label updates to Buvidal® for treatment of opioid dependence

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Camurus Ab (0RD1) Actualités

Camurus Ab (0RD1)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

0RD1 Actualités

Camurus announces new Phase 3 data reinforcing long-term safety and efficacy of octreotide SC depot (CAM2029) in patients with acromegaly

Camurus announces new Phase 3 data reinforcing long-term safety and efficacy of octreotide SC depot (CAM2029) in patients with acromegaly

Camurus announces FDA approval of Brixadi™ for the treatment of moderate to severe opioid use disorder

Camurus announces FDA approval of Brixadi™ for the treatment of moderate to severe opioid use disorder

Braeburn receives new Complete Response Letter for Brixadi in the US

FDA grants Orphan Drug Designation in the US for CAM2029 for the treatment of polycystic liver disease

FDA grants Orphan Drug Designation in the US for CAM2029 for the treatment of polycystic liver disease

Camurus announces PDUFA date for Brixadi for the treatment of opioid use disorder in the US

Camurus announces PDUFA date for Brixadi for the treatment of opioid use disorder in the US

Camurus announces Braeburn resubmits New Drug Application for Brixadi™ in the US

Camurus announces Braeburn resubmits New Drug Application for Brixadi™ in the US

Camurus announces publication showing superior patient treatment satisfaction with Buvidal® weekly and monthly depot injecti...

Camurus announces publication showing superior patient treatment satisfaction with Buvidal® weekly and monthly depot injecti...

The Australian TGA approves key label updates to Buvidal® for treatment of opioid dependence

The Australian TGA approves key label updates to Buvidal® for treatment of opioid dependence

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités